Table 2 Annual mortality rates in the first six months of treatment for men and women in the Southeast region starting ART in 2010
CD4 cell count | Age | Male | Female |
|---|---|---|---|
CD4 ≥ 500 | 20 | 0.010 (0.008–0.011) | 0.007 (0.006–0.008) |
30 | 0.013 (0.012–0.015) | 0.009 (0.008–0.010) | |
40 | 0.018 (0.017–0.020) | 0.013 (0.011–0.014) | |
50 | 0.025 (0.023–0.027) | 0.018 (0.016–0.019) | |
CD4 350–499 | 20 | 0.015 (0.013–0.017) | 0.012 (0.010–0.013) |
30 | 0.020 (0.018–0.022) | 0.016 (0.014–0.017) | |
40 | 0.026 (0.024–0.028) | 0.021 (0.019–0.023) | |
50 | 0.035 (0.032–0.037) | 0.027 (0.024–0.030) | |
CD4 200–349 | 20 | 0.026 (0.024–0.028) | 0.020 (0.018–0.021) |
30 | 0.032 (0.030–0.034) | 0.024 (0.022–0.026) | |
40 | 0.039 (0.037–0.041) | 0.029 (0.028–0.031) | |
50 | 0.048 (0.045–0.050) | 0.036 (0.034–0.038) | |
CD4 < 200 | 20 | 0.089 (0.085–0.093) | 0.073 (0.069–0.077) |
30 | 0.097 (0.094–0.101) | 0.080 (0.076–0.084) | |
40 | 0.107 (0.103–0.111) | 0.088 (0.084–0.091) | |
50 | 0.1117 (0.110–0.122) | 0.096 (0.092–0.100) |